UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Diagnostic approach to the patient with polycythemia

Author
Ayalew Tefferi, MD
Section Editor
Stanley L Schrier, MD
Deputy Editor
Jennifer S Tirnauer, MD

INTRODUCTION

Polycythemia is a laboratory finding in which there is an increased number of red blood cells (RBC), along with an accompanying increase in the concentration of hemoglobin in the peripheral blood. The approach to the patient with polycythemia will be reviewed here. The approach to confirming a diagnosis of polycythemia vera is discussed separately. (See "Clinical manifestations and diagnosis of polycythemia vera".)

TERMINOLOGY

The red blood cell (RBC) count, hemoglobin (HGB), and hematocrit (HCT) are concentrations and therefore dependent upon the plasma volume as well as the total RBC mass (RCM).

Relative polycythemia — An isolated decrease in plasma volume can elevate the HGB, HCT, and RBC count without increasing the RCM; this is referred to as relative polycythemia. The state of chronically reduced plasma volume with elevated HGB or HCT has been called Gaisbock's disease, spurious polycythemia, stress erythrocytosis, apparent polycythemia, and pseudopolycythemia [1-4], although many may be examples of smokers' polycythemia (see 'Reduced plasma volume' below) [5].

Absolute polycythemia — In absolute polycythemia (also called erythrocytosis) there is an increased RCM. Patients are further categorized into primary and secondary forms (table 1).

Primary polycythemia — Primary polycythemia is caused by an acquired or inherited mutation leading to an abnormality within RBC progenitors; it includes polycythemia vera (PV) and rare familial variants (eg, activating mutations of the erythropoietin receptor, Chuvash polycythemia). (See "Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera".)

                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri Nov 04 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. LAWRENCE JH, BERLIN NI. Relative polycythemia; the polycythemia of stress. Yale J Biol Med 1952; 24:498.
  2. Berlin NI, Wasserman LR. Polycythemia vera: a retrospective and reprise. J Lab Clin Med 1997; 130:365.
  3. Brown SM, Gilbert HS, Krauss S, Wasserman LR. Spurious (relative) polycythemia: a nonexistent disease. Am J Med 1971; 50:200.
  4. Weinreb NJ. Relative polycythemia. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.226.
  5. Smith JR, Landaw SA. Smokers' polycythemia. N Engl J Med 1978; 298:6.
  6. Messinezy M, Sawyer B, Westwood NB, Pearson TC. Idiopathic erythrocytosis--additional new study techniques suggest a heterogenous group. Eur J Haematol 1994; 53:163.
  7. Rossi D, Cortini F, Deambrogi C, et al. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. Leuk Res 2007; 31:97.
  8. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459.
  9. Tefferi A. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications. N Engl J Med 2007; 356:444.
  10. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med 1997; 102:14.
  11. Birgegård G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol 1992; 81:603.
  12. Weinberg RS. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin Hematol 1997; 34:64.
  13. Najean Y, Schlageter MH, Toubert ME, Podgorniak MP. Radioimmunoassay of immunoreactive erythropoietin as a clinical tool for the classification of polycythaemias. Nouv Rev Fr Hematol 1990; 32:237.
  14. Remacha AF, Montserrat I, Santamaria A, et al. Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. Haematologica 1997; 82:406.
  15. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130:174.
  16. Keohane C, McMullin MF, Harrison C. The diagnosis and management of erythrocytosis. BMJ 2013; 347:f6667.
  17. Krauss DJ, Taub HA, Lantinga LJ, et al. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991; 146:1566.
  18. Aitchison R, Russell N. Smoking--a major cause of polycythaemia. J R Soc Med 1988; 81:89.
  19. Pollak R, Maddux MS, Cohan J, et al. Erythrocythemia following renal transplantation: influence of diuretic therapy. Clin Nephrol 1988; 29:119.
  20. Sakisaka S, Watanabe M, Tateishi H, et al. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology 1993; 18:1357.
  21. Kew MC, Fisher JW. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 1986; 58:2485.
  22. Da Silva JL, Lacombe C, Bruneval P, et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 1990; 75:577.
  23. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.
  24. Pearson TC, Messinezy M. Investigation of patients with polycythaemia. Postgrad Med J 1996; 72:519.
  25. Bernard PJ. Measurement of red-cell and plasma volumes. Nouv Rev Fr Hematol 1994; 36:155.
  26. Fairbanks VF, Klee GG, Wiseman GA, et al. Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. Blood Cells Mol Dis 1996; 22:169.
  27. Holme S, Elfath MD, Heaton A, et al. Prediction of red cell and blood volumes distribution by various nomograms: do current nomograms overestimate? Transfusion 2008; 48:910.
  28. Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. Eur J Appl Physiol 2005; 95:486.
  29. Mock DM, Matthews NI, Strauss RG, et al. Red blood cell volume can be independently determined in vitro using sheep and human red blood cells labeled at different densities of biotin. Transfusion 2009; 49:1178.
  30. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89:748.
  31. Ferrant A. What clinical and laboratory data are indicative of polycythemia and when are blood volume studies needed? Nouv Rev Fr Hematol 1994; 36:151.
  32. BUTTON LN, GIBSON JG 2nd, WALTER CW. SIMULTANEOUS DETERMINATION OF THE VOLUME OF RED CELLS AND PLASMA FOR SURVIVAL STUDIES OF STORED BLOOD. Transfusion 1965; 5:143.
  33. Nielsen S, Rødbro P. Validity of rapid estimation of erythrocyte volume in the diagnosis of polycytemia vera. Eur J Nucl Med 1989; 15:32.
  34. Spivak JL. The optimal management of polycythaemia vera. Br J Haematol 2002; 116:243.
  35. Fairbanks VF, Tauxe WN. Plasma and erythrocyte volumes in obesity, polycythemia, and related conditions. In: , Pools and Spaces in Medical Physiology, USAEC Division of Technical Information, Oak Ridge, TN 1967. p.283.
  36. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100:4272.
  37. Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013; 122:1881.
  38. Landaw SA. Polycythemia vera and other polycythemic states. Clin Lab Med 1990; 10:857.
  39. Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34:70.
  40. Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997; 89:4628.
  41. Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90:2057.
  42. Messinezy M, Westwood NB, El-Hemaidi I, et al. Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. Br J Haematol 2002; 117:47.
  43. Prchal JT, Sokol L. "Benign erythrocytosis" and other familial and congenital polycythemias. Eur J Haematol 1996; 57:263.
  44. Copelan EA, Balcerzac SP. Secondary polycythemia. In: Polycythemia Vera and the Myeloproliferative Disorders, Wasserman LR, Berk PD, Berlin NI (Eds), WB Saunders, Philadelphia 1995. p.195.
  45. Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991; 78:3066.
  46. Distelhorst CW, Wagner DS, Goldwasser E, Adamson JW. Autosomal Dominant familial erythrocytosis due to autonomous erythropoietin production. Blood 1981; 58:1155.
  47. Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24:1.
  48. Brox AG, Mangel J, Hanley JA, et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation 1998; 66:1053.
  49. Chagnac A, Zevin D, Weinstein T, et al. Erythrocytosis associated with renal artery thrombosis in a patient with polycystic kidney disease on hemodialysis. Acta Haematol 1990; 84:40.
  50. Bacon BR, Rothman SA, Ricanati ES, Rashad FA. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med 1980; 140:1206.
  51. Schramek A, Better OS, Adler O, et al. Hypertensive crisis, erythrocytosis, and uraemia due to renal-artery stenosis of kidney transplants. Lancet 1975; 1:70.
  52. Drénou B, Le Tulzo Y, Caulet-Maugendre S, et al. Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouv Rev Fr Hematol 1995; 37:197.
  53. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996; 93:10595.
  54. Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002; 99:3562.
  55. Yoshida M, Koshiyama M, Fujii H, Konishi M. Erythrocytosis and a fibroid. Lancet 1999; 354:216.
  56. Suzuki M, Takamizawa S, Nomaguchi K, et al. Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis. Br J Haematol 2001; 113:49.
  57. LevGur M, Levie MD. The myomatous erythrocytosis syndrome: a review. Obstet Gynecol 1995; 86:1026.
  58. Lanne JS, Dumortier J, Hervieu V, et al. Polycythemia and elevated serum erythropoietin associated with a liver haemangioma. Gastroenterol Clin Biol 2010; 34:629.
  59. Weisse AB, Moschos CB, Frank MJ, et al. Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels. Am J Med 1975; 58:92.
  60. HARVEY RM, FERRER MI, COURNAND A. The treatment of chronic cor pulmonale. Circulation 1953; 7:932.
  61. AUCHINCLOSS JH Jr, DUGGAN JJ. Effects of venesection on pulmonary and cardiac function in patients with chronic pulmonary emphysema and secondary polycythemia. Am J Med 1957; 22:74.
  62. Chetty KG, Brown SE, Light RW. Improved exercise tolerance of the polycythemic lung patient following phlebotomy. Am J Med 1983; 74:415.